ACADIA PHARMACEUTICALS INC. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on central nervous system (CNS) disorders and rare diseases. Its commercial portfolio consists of NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome. The company operates as a single business segment with revenues generated primarily in North America.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $264,566 | $241,963 | $508,882 | $447,794 |
| Net Income | $26,666 | $33,389 | $45,653 | $49,944 |
| Diluted EPS | $0.16 | $0.20 | $0.27 | $0.30 |
| Operating Cash Flow (YTD) | $84,279 (2025) vs $54,092 (2024) | |||
| Cash & Investments (End of Period) | $762.0 million (Cash: $253.6M + Investments: $508.4M) | |||
| Accumulated Deficit | $(2,158,733) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9.3% year-over-year in Q2 2025. NUPLAZID sales rose to $168.5M (from $157.4M), and DAYBUE sales increased to $96.1M (from $84.6M), driven by unit volume growth and higher average net selling prices.
- Profitability Decline: Despite revenue growth, Net Income decreased 20.1% in Q2 2025 compared to Q2 2024. This was primarily due to a significant increase in income tax expense ($13.5M vs $3.8M), resulting in an effective tax rate of 33.7% compared to 10.2% in the prior year.
- Expense Increases:
- R&D Expenses: Increased to $78.0M in Q2 2025 (from $76.2M), driven by higher expenditures for product candidates ACP-204 and ACP-101.
- SG&A Expenses: Increased to $133.5M in Q2 2025 (from $117.1M), attributed to expanded commercial teams for DAYBUE and NUPLAZID.
- Investing Activities: Net cash used in investing activities increased significantly to $167.3M YTD 2025 (from $70.2M YTD 2024), primarily due to increased net purchases of investment securities and a $98.8M outflow for intangible assets.
Guidance, Outlook, and Risks
- Pipeline Milestones: The company expects to report top-line results from the Phase 3 COMPASS PWS study for ACP-101 (Prader-Willi syndrome) in early Q4 2025. An NDA submission is planned for Q1 2026 if results are positive.
- Regulatory & Tax: On July 4, 2025, the "One Big Beautiful Bill Act" (OBBBA) was signed into law, making permanent key elements of the Tax Cuts and Jobs Act. The company is evaluating the impact on deferred tax balances, with effects expected to be recognized in Q3 2025.
- Legal Proceedings:
- Patent Litigation: The Federal Circuit affirmed the District Court's judgment in Acadia's favor regarding NUPLAZID patent infringement against MSN Laboratories (June 9, 2025). Defendants have appealed. A similar judgment was issued against Aurobindo, also appealed.
- Securities Litigation: A securities class action regarding the sNDA for pimavanserin remains in expert discovery. A related derivative suit is stayed pending the outcome of the class action.
- Liquidity: Management expects current cash, cash equivalents, and investment securities to be sufficient to fund operations through and beyond the next 12 months.
Key Investor Verification Points
- Tax Rate Volatility: Verify the sustainability of the 33.7% effective tax rate in Q2 2025 compared to 10.2% in Q2 2024 and the specific impact of the new OBBBA legislation on future tax provisions.
- ACP-101 Phase 3 Results: Monitor the upcoming Q4 2025 top-line data for the COMPASS PWS study, which is critical for the company's growth strategy beyond its current two products.
- Patent Expiry & Litigation: Track the appeals process in the NUPLAZID patent infringement cases against MSN and Aurobindo, as a reversal could impact future revenue protection.
- DAYBUE Cost of Sales: Monitor the transition from "zero cost" inventory to full-cost inventory for DAYBUE, which is expected to increase the cost of sales as a percentage of net sales in late 2025.